---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070336"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T17:00:01.307436+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Erasca Q1 net loss $31M; cash $411M; IND cleared for ERAS-0015; cash runway to H2 2028

## Summary
- Net loss was $31.0M ($0.11/sh) vs $35.0M ($0.23/sh) in Q1 2024; R&D spend decreased to $26.0M from $28.6M.
- Cash, equivalents & marketable securities $411.1M at March 31, 2025; cash runway extended to H2 2028.
- IND cleared for pan-RAS molecular glue ERAS-0015; IND submitted for pan-KRAS inhibitor ERAS-4001.
- Initial Phase 1 monotherapy data for both ERAS-0015 and ERAS-4001 expected in 2026.
- Pursuing partnership opportunities for naporafenib to focus on RAS-targeting franchise.

## SEC filing metadata
- accession: 0000950170-25-070336
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017025070336/0000950170-25-070336-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017025070336/eras-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070336
- JSON: https://secwatch.observer/filing/0000950170-25-070336.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070336.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.